IsoPlexis is a biotechnology company specializing in single cell proteomics, providing advanced tools for immune medicine research. The company serves clients in the pharmaceutical, biotech, and medical center sectors, focusing on therapies and diagnostics based on biologics and the immune system. IsoPlexis operates in the global healthcare market, offering an all-in-one, intuitive system that fits on any lab bench, known as the IsoLight system. This system detects the most potent cells secreting multiple cytokines at high intensity, providing unique insights unattainable with other systems. IsoPlexis generates revenue through the sale of its proprietary IsoLight system and related consumables, as well as through strategic partnerships and collaborations with industry leaders. The company's business model is centered around providing high-value, cutting-edge technology that accelerates research and improves patient outcomes.

Keywords: single cell proteomics, immune medicine, IsoLight system, cytokine detection, cancer immunology, CAR T cell therapy, biotech, pharmaceutical research, medical diagnostics, strategic partnerships.